IFN-beta

IFN-beta 분자 정보

영어 이름Interferon beta시판 약물 수1
임상 약물 수6표적 별명Interferon Beta 1,Interferon, Beta 1, Fibroblast,IFNB,IFB,IFF,Interferon-beta,IFN-beta,Fibroblast interferon,IFNB1,Interferon beta
최고 연구 개발 단계Approved
영어 이름Interferon beta
표적 별명Interferon Beta 1,Interferon, Beta 1, Fibroblast,IFNB,IFB,IFF,Interferon-beta,IFN-beta,Fibroblast interferon,IFNB1,Interferon beta
시판 약물 수1
임상 약물 수6
최고 연구 개발 단계Approved

IFN-beta 제품 목록

  • 속성

    Protein (3)

  • 제품 라이브러리

    온라인 (3)

  • Human (2)Mouse (1)

  • 태그

    Fc Tag (1)His Tag & Avi Tag (2)

  • 마커

    Unconjugated (1)Biotin-labeled (2)

IFN-beta분자 배경

Interferon beta(IFN beta) is type I interferon cytokine that plays a key role in the innate immune response to infection, developing tumors and other inflammatory stimuli. Signals via binding to high-affinity (IFNAR2) and low-affinity (IFNAR1) heterodimeric receptor, activating the canonical Jak-STAT signaling pathway resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response, such as antiviral proteins, regulators of cell proliferation and differentiation, and immunoregulatory proteins. IFNB1 is more potent than interferon-alpha (IFN-alpha) in inducing the apoptotic and antiproliferative pathways required for control of tumor cell growth (By similarity)

IFN-beta분자 별명

IFNB1,Interferon beta,IFN-beta,IFB,IFNB

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
DazukibartPF-06823859Phase 3 ClinicalPfizer IncDermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases; Myositis; Polymyositis
상세
Peginterferon beta-1a (CinnaGen)Phase 3 ClinicalCinnagenMultiple Sclerosis, Relapsing-Remitting
상세
VSV-IFNbeta-NISPhase 2 ClinicalVyriadAngioimmunoblastic T-cell Lymphoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Histiocytoma; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
상세
VSV-hIFNbeta-NIS (University of Tennessee)Phase 1 ClinicalThe University Of TennesseeEndometrial Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Multiple Myeloma
상세
MEM-288MEM-288Phase 1 ClinicalMemgenCarcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms
상세
SCD-153SCD-153Phase 1 ClinicalInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University, Sun Pharma Advanced Research Company LtdAlopecia Areata
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
PropagermaniumSK-818; SK-818CApprovedSanwa Kagaku Kenkyusho Co LtdSerocionJapanHepatitis BSanwa Kagaku Kenkyusho Co Ltd1994-01-01Hepatitis B
상세
  • 분자 정보
  • 제품 목록
  • 시판 약물 정보
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호